S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:CYTH

Cyclo Therapeutics (CYTH) Stock Price, News & Analysis

$1.39
-0.01 (-0.71%)
(As of 03/28/2024 ET)
Today's Range
$1.38
$1.42
50-Day Range
$1.39
$1.90
52-Week Range
$0.67
$2.57
Volume
30,476 shs
Average Volume
151,826 shs
Market Capitalization
$39.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Cyclo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
187.8% Upside
$4.00 Price Target
Short Interest
Healthy
0.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Cyclo Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.32 out of 5 stars

Medical Sector

567th out of 939 stocks

Biological Products, Except Diagnostic Industry

95th out of 156 stocks

CYTH stock logo

About Cyclo Therapeutics Stock (NASDAQ:CYTH)

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

CYTH Stock Price History

CYTH Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Cyclo Therapeutics, Inc. (CYTH)
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Cyclo Therapeutics Inc CYTH
Cyclo Therapeutics reports Q3 results
WISH, REAL and PIXY among mid-day movers
See More Headlines
Receive CYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/17/2023
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTH
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+187.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,060,000.00
Net Margins
-1,864.03%
Pretax Margin
-1,864.03%

Debt

Sales & Book Value

Annual Sales
$1.08 million
Book Value
$0.21 per share

Miscellaneous

Free Float
20,164,000
Market Cap
$39.92 million
Optionable
No Data
Beta
-0.14
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

CYTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Cyclo Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTH shares.
View CYTH analyst ratings
or view top-rated stocks.

What is Cyclo Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price targets for Cyclo Therapeutics' stock. Their CYTH share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 187.8% from the stock's current price.
View analysts price targets for CYTH
or view top-rated stocks among Wall Street analysts.

How have CYTH shares performed in 2024?

Cyclo Therapeutics' stock was trading at $1.59 at the beginning of the year. Since then, CYTH shares have decreased by 12.6% and is now trading at $1.39.
View the best growth stocks for 2024 here
.

Are investors shorting Cyclo Therapeutics?

Cyclo Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 112,600 shares, an increase of 77.9% from the February 29th total of 63,300 shares. Based on an average daily trading volume, of 114,500 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.9% of the company's shares are short sold.
View Cyclo Therapeutics' Short Interest
.

When is Cyclo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CYTH earnings forecast
.

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) released its quarterly earnings data on Friday, March, 17th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.34. The firm had revenue of $0.19 million for the quarter. Cyclo Therapeutics had a negative net margin of 1,864.03% and a negative trailing twelve-month return on equity of 4,506.97%.

Who are Cyclo Therapeutics' major shareholders?

Cyclo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Founders Fund V Management LLC (2.11%), Vanguard Group Inc. (1.56%), Vanguard Group Inc. (1.56%), Founders Fund VI Management LLC (0.48%), Citadel Advisors LLC (0.24%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Francis Patrick Ostronic, Jeffrey Tate, Joshua M Fine, Markus Sieger, N Scott Fine, Rafael Holdings, Inc and Sharon Hemond Hrynkow.
View institutional ownership trends
.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTH) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners